271 related articles for article (PubMed ID: 8067197)
1. [Use of interferon in patients with hairy cell leukemia and myeloproliferative disorders].
Skotnicki AB; Wolska-Smoleń T
Acta Haematol Pol; 1994; 25(2 Suppl 1):124-35. PubMed ID: 8067197
[TBL] [Abstract][Full Text] [Related]
2. [Use of interferon in the treatment of chronic myeloproliferative disorders].
Robak T
Acta Haematol Pol; 1992; 23(2 Suppl 1):30-7. PubMed ID: 1488870
[TBL] [Abstract][Full Text] [Related]
3. [Interferon-alpha in the treatment of myeloproliferative syndromes].
Ballarino P; Castello G; Lerza R
Recenti Prog Med; 1994 Nov; 85(11):546-50. PubMed ID: 7855389
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of alpha interferon and hydroxyurea in late phase refractory myeloproliferative disease.
Litam PP; Landaw SA; Zamkoff KW
Haematologia (Budap); 1994; 26(2):87-90. PubMed ID: 7890266
[TBL] [Abstract][Full Text] [Related]
5. Interferon in the treatment of myeloproliferative diseases.
Silver RT
Semin Hematol; 1990 Jul; 27(3 Suppl 4):6-14. PubMed ID: 2115694
[TBL] [Abstract][Full Text] [Related]
6. Alpha interferon: progress and perspectives in the biotherapy of chronic myelogenous leukemia.
Habermann TM
Oncol Nurs Forum; 1989; 16(6 Suppl):8-11. PubMed ID: 2687814
[TBL] [Abstract][Full Text] [Related]
7. Use of interferon in the treatment of chronic myelogenous leukemia.
Talpaz M
Semin Oncol; 1994 Dec; 21(6 Suppl 14):3-7. PubMed ID: 7992097
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of interferon action in hairy cell leukemia: a model of effective cancer biotherapy.
Vedantham S; Gamliel H; Golomb HM
Cancer Res; 1992 Mar; 52(5):1056-66. PubMed ID: 1737364
[TBL] [Abstract][Full Text] [Related]
9. High response rate using recombinant interferon-alpha in patients with newly diagnosed chronic myeloid leukemia.
Mahon FX; Fabères C; Montastruc M; Si-Mour S; Boiron JM; Marit G; Bilhou-Nabera C; Cony-Makhoul P; Pigneux A; Bernard P; Broustet A; Reiffers J
Bone Marrow Transplant; 1996 May; 17 Suppl 3():S33-7. PubMed ID: 8769698
[TBL] [Abstract][Full Text] [Related]
10. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of hairy-cell leukemia using interferon alfa].
Neuwirtová R; Cermák J; Kvasnicka J; Sedlácková M
Cas Lek Cesk; 1989 Aug; 128(34):1065-70. PubMed ID: 2790914
[TBL] [Abstract][Full Text] [Related]
12. Prior treatment with alpha-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia.
Zuffa E; Bandini G; Bonini A; Santucci MA; Martinelli G; Rosti G; Testoni N; Zaccaria A; Tura S
Haematologica; 1998 Mar; 83(3):231-6. PubMed ID: 9573677
[TBL] [Abstract][Full Text] [Related]
13. [Treatment with lymphoblastoid alpha interferon in patients with chronic myeloid leukemia refractory to recombinant interferon alpha 2].
Steegmann JL; Granados E; Vázquez L; de la Cámara R; Peñarrubia MJ; Fernández-Contreras E; Quiroga JA; Fernández Rañada JM
Sangre (Barc); 1998 Oct; 43(5):443-6. PubMed ID: 9868341
[TBL] [Abstract][Full Text] [Related]
14. [The therapeutic effect of interferon-alpha exemplified by hairy cell leukemia].
Schwarzmeier JD
Wien Med Wochenschr; 1993; 143(16-17):412-5. PubMed ID: 8273363
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group.
Radin AI; Kim HT; Grant BW; Bennett JM; Kirkwood JM; Stewart JA; Hahn RG; Dutcher JP; Wiernik PH; Oken MM;
Cancer; 2003 Jul; 98(1):100-9. PubMed ID: 12833462
[TBL] [Abstract][Full Text] [Related]
16. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
[TBL] [Abstract][Full Text] [Related]
17. Introduction and overview of interferon alfa in myeloproliferative and hemangiomatous diseases.
Appelbaum FR
Semin Hematol; 1990 Jul; 27(3 Suppl 4):1-5. PubMed ID: 2197729
[TBL] [Abstract][Full Text] [Related]
18. Interferon-alpha lymphoblastoid in chronic myeloid leukemia patients unresponsive to recombinant IFN alpha 2.
Steegmann JL; Granados E; Peñarrubia MJ
Haematologica; 1997; 82(6):731-2. PubMed ID: 9580090
[No Abstract] [Full Text] [Related]
19. alpha-Interferon in hematological malignancies.
Giles FJ; Ozer H
Curr Opin Biotechnol; 1991 Dec; 2(6):847-50. PubMed ID: 1367959
[TBL] [Abstract][Full Text] [Related]
20. [Interferon alpha in the treatment of chronic myeloid leukemia].
Tóthová E; Fricová M; Stecová N; Svorcová E; Surová M; Kafková A; Guman T; Mudronová B
Vnitr Lek; 1996 May; 42(5):327-30. PubMed ID: 8768291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
